# OnCo record irae-skin (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-skin/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-skin" ;
  schema:name "Immune-related skin reactions from checkpoint inhibitors, including blistering and severe erosive rashes"@en ;
  schema:alternateName "checkpoint inhibitor rash"@en, "immunotherapy skin toxicity"@en, "ICI bullous pemphigoid"@en, "ICI SJS/TEN"@en, "dermatologic irAE"@en, "D-irAE"@en ;
  schema:description "Rash and itching are among the commonest and earliest side effects of immunotherapy, usually a few weeks in, and most are mild. Blisters, peeling skin, sore skin, or sores in the mouth, eyes or genitals are different: they can be serious and need the cancer team the same day."@en ;
  schema:url <https://onco.cc/protocols/irae-skin/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "dermatology" ;
  onco:related <https://onco.cc/protocols/irae-colitis/>, <https://onco.cc/protocols/checkpoint-inhibitor-baseline-and-monitoring/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/rituximab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/> .